4-(piperazin-1-yl)-2-(thiophen-2-yl)quinazoline | 1264533-32-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-(piperazin-1-yl)-2-(thiophen-2-yl)quinazoline
• 英文别名: 4-Piperazin-1-yl-2-thiophen-2-ylquinazoline
• CAS: 1264533-32-5
• 化学式: C₁₆H₁₆N₄S
• 分子量: 296.396
• InChiKey: YUMKOTAGTXQSIM-UHFFFAOYSA-N

物化性质

• 沸点：
  424.4±43.0 °C(Predicted)
• 密度：
  1.271±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  69.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  间甲苯磺酰氯 、 4-(piperazin-1-yl)-2-(thiophen-2-yl)quinazoline 在 N,N-二异丙基乙胺 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 3.0h， 以29%的产率得到4-(4-(3-methylphenylsulfonyl)piperazin-1-yl)-2-(thiophen-2-yl)quinazoline
  参考文献：
  名称：

  Evaluation of Quinazoline Analogues as Glucocerebrosidase Inhibitors with Chaperone Activity

  摘要：

  Gaucher disease is a lysosomal storage disorder (LSD) caused by deficiency in the enzyme glucocerebrosidase (GC). Small molecule chaperones of protein folding and translocation have been proposed as a promising therapeutic approach to this LSD. Most small molecule chaperones described in the literature contain an iminosugar scaffold. Here we present the discovery and evaluation of a new series of GC inhibitors with a quinazoline core. We demonstrate that this series can improve the translocation of GC to the lysosome in patient-derived cells. To optimize this chemical series, systematic synthetic modifications were performed and the SAR was evaluated and compared using three different readouts of compound activity: enzymatic inhibition, enzyme thermostabilization, and lysosomal translocation of GC.

  DOI：

  10.1021/jm1008902
• 作为产物：
  描述：

  tert-butyl 4-(2-chloroquinazolin-4-yl)piperazine-1-carboxylate 在 盐酸 、 bis-triphenylphosphine-palladium(II) chloride 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 32.0h， 生成 4-(piperazin-1-yl)-2-(thiophen-2-yl)quinazoline
  参考文献：
  名称：

  Evaluation of Quinazoline Analogues as Glucocerebrosidase Inhibitors with Chaperone Activity

  摘要：

  Gaucher disease is a lysosomal storage disorder (LSD) caused by deficiency in the enzyme glucocerebrosidase (GC). Small molecule chaperones of protein folding and translocation have been proposed as a promising therapeutic approach to this LSD. Most small molecule chaperones described in the literature contain an iminosugar scaffold. Here we present the discovery and evaluation of a new series of GC inhibitors with a quinazoline core. We demonstrate that this series can improve the translocation of GC to the lysosome in patient-derived cells. To optimize this chemical series, systematic synthetic modifications were performed and the SAR was evaluated and compared using three different readouts of compound activity: enzymatic inhibition, enzyme thermostabilization, and lysosomal translocation of GC.

  DOI：

  10.1021/jm1008902

文献信息

• Copper mediated one-pot synthesis of quinazolinones and exploration of piperazine linked quinazoline derivatives as anti-mycobacterial agents
  作者：Satyaveni Malasala、Jitendra Gour、Md. Naiyaz Ahmad、Srikanth Gatadi、Manjulika Shukla、Grace Kaul、Arunava Dasgupta、Y. V. Madhavi、Sidharth Chopra、Srinivas Nanduri

  DOI：10.1039/d0ra08644d

  日期：——

  A facile method was developed for the synthesis of quinazolinone derivatives in a one-pot condensation reaction via in situ amine generation using ammonia as the amine source and with the formation of four new C–N bonds in good to excellent yields. With the optimised method, we synthesized a library of piperazine linked quinazoline derivatives and the synthesized compounds were evaluated for their

  开发了一种简便的方法，通过使用氨作为胺源，通过原位生成胺，在一锅缩合反应中合成喹唑啉酮衍生物，并形成四个新的 C-N 键，产率良好至优异。通过优化的方法，我们合成了哌嗪连接的喹唑啉衍生物库，并评价了合成的化合物对结核分枝杆菌的抑制活性。化合物8b 、 8e 、 8f 、 8m 、 8n和8v显示出有效的抗分枝杆菌活性，MIC值为2-16 μg mL -1 。所有合成的化合物都遵循 Lipinski 的药物相似规则。
• Evaluation of Quinazoline Analogues as Glucocerebrosidase Inhibitors with Chaperone Activity
  作者：Juan J. Marugan、Wei Zheng、Omid Motabar、Noel Southall、Ehud Goldin、Wendy Westbroek、Barbara K. Stubblefield、Ellen Sidransky、Ronald A. Aungst、Wendy A. Lea、Anton Simeonov、William Leister、Christopher P. Austin

  DOI：10.1021/jm1008902

  日期：2011.2.24

  Gaucher disease is a lysosomal storage disorder (LSD) caused by deficiency in the enzyme glucocerebrosidase (GC). Small molecule chaperones of protein folding and translocation have been proposed as a promising therapeutic approach to this LSD. Most small molecule chaperones described in the literature contain an iminosugar scaffold. Here we present the discovery and evaluation of a new series of GC inhibitors with a quinazoline core. We demonstrate that this series can improve the translocation of GC to the lysosome in patient-derived cells. To optimize this chemical series, systematic synthetic modifications were performed and the SAR was evaluated and compared using three different readouts of compound activity: enzymatic inhibition, enzyme thermostabilization, and lysosomal translocation of GC.